HomeCompareSGIOY vs ABBV

SGIOY vs ABBV: Dividend Comparison 2026

SGIOY yields 1.82% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGIOY wins by $539.4K in total portfolio value· pulled ahead in Year 6
10 years
SGIOY
SGIOY
● Live price
1.82%
Share price
$11.09
Annual div
$0.20
5Y div CAGR
70.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$641.7K
Annual income
$420,841.59
Full SGIOY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SGIOY vs ABBV

📍 SGIOY pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGIOYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGIOY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGIOY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGIOY
Annual income on $10K today (after 15% tax)
$154.36/yr
After 10yr DRIP, annual income (after tax)
$357,715.35/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SGIOY beats the other by $336,659.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGIOY + ABBV for your $10,000?

SGIOY: 50%ABBV: 50%
100% ABBV50/50100% SGIOY
Portfolio after 10yr
$372.0K
Annual income
$222,806.68/yr
Blended yield
59.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SGIOY
No analyst data
Altman Z
10.6
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGIOY buys
0
ABBV buys
0
No recent congressional trades found for SGIOY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGIOYABBV
Forward yield1.82%3.06%
Annual dividend / share$0.20$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR70.4%40.6%
Portfolio after 10y$641.7K$102.3K
Annual income after 10y$420,841.59$24,771.77
Total dividends collected$599.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGIOY vs ABBV ($10,000, DRIP)

YearSGIOY PortfolioSGIOY Income/yrABBV PortfolioABBV Income/yrGap
1$11,009$309.44$11,550$430.00$541.00ABBV
2$12,323$542.53$13,472$627.96$1.1KABBV
3$14,152$967.05$15,906$926.08$1.8KABBV
4$16,912$1,768.72$19,071$1,382.55$2.2KABBV
5$21,461$3,365.93$23,302$2,095.81$1.8KABBV
6← crossover$29,766$6,802.41$29,150$3,237.93+$616.00SGIOY
7$46,875$15,024.95$37,536$5,121.41+$9.3KSGIOY
8$87,836$37,680.36$50,079$8,338.38+$37.8KSGIOY
9$206,429$112,444.03$69,753$14,065.80+$136.7KSGIOY
10$641,720$420,841.59$102,337$24,771.77+$539.4KSGIOY

SGIOY vs ABBV: Complete Analysis 2026

SGIOYStock

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Full SGIOY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SGIOY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGIOY vs SCHDSGIOY vs JEPISGIOY vs OSGIOY vs KOSGIOY vs MAINSGIOY vs JNJSGIOY vs MRKSGIOY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.